Ruth Catharina de Lange Davies is Professor of Biophysics at the Norwegian University of Science and Technology. Her research specializes in ultrasound-mediated drug delivery systems, particularly nanoparticle transport mechanisms in tumors and advanced imaging techniques for real-time therapeutic monitoring. Core research domains: Ultrasound-enhanced drug delivery using microbubbles Acoustic Cluster Therapy (ACT) development Intravital multiphoton microscopy techniques Nanoparticle-tissue interactions Hydrogel transport dynamics Her recent publications demonstrate innovative approaches to overcoming biological barriers in drug delivery. Studies utilizing high-speed optical characterization reveal how microbubble composition affects ultrasound-triggered drug release, while intravital microscopy work visualizes real-time drug extravasation dynamics. Molecular dynamics simulations complement experimental findings on ultrasound-enhanced diffusion mechanisms. Davies' team investigates tumor-specific responses to ultrasound interventions, noting significant variations in vascular effects depending on tumor type and microbubble characteristics. This work informs precision applications of acoustic therapies in oncology.
Dr. William Anderson is a researcher affiliated with the School of Medicine's Department of Respiratory Medicine. His work focuses on advancing clinical understanding of COPD, asthma, and pharmacotherapeutic interventions. Key areas include beta-blocker efficacy in COPD patients, inhaled corticosteroid dosing strategies, small airway dysfunction, and biomarker-driven lung cancer screening. His research integrates clinical trials, pharmacogenomics, and advanced diagnostic techniques like impulse oscillometry. Recent studies investigate left ventricular hypertrophy's impact on COPD prognosis and genotype-guided asthma management. Dr. Anderson has contributed to over 30 peer-reviewed publications since 2009, emphasizing translational research between preclinical models and clinical practice. Education details are not explicitly stated in the provided text. His research portfolio includes randomized controlled trials evaluating drug efficacy (e.g., bisoprolol vs celiprolol in COPD, autoantibody-based lung cancer screening), pharmacokinetic studies of inhaled medications, and explorations of β2-adrenergic receptor polymorphisms' effects on asthma control. Collaborative studies with cardiovascular specialists address cardiopulmonary comorbidities in COPD patients. Current efforts focus on improving COPD management through better understanding of dynamic hyperinflation mechanisms and domiciliary safety protocols. No scientific awards are listed in the provided information. His work involves multidisciplinary teams addressing unmet needs in small airways disease and corticosteroid optimization. Ongoing projects include refining inhaled corticosteroid particle size formulations and evaluating real-world outcomes of long-acting bronchodilator use in COPD.
Associate Professor Dan Wright is a clinical pharmacology expert at the Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney. He holds a pharmacy degree from Dalhousie University, an MSc in Clinical Pharmacology, and a PhD from the University of Otago. His work focuses on medication adherence, population pharmacokinetics, and precision dosing, with extensive experience in hospital pharmacy practice. Education: B Pharm (Dalhousie University) MSc in Clinical Pharmacology (University of Otago) PhD (University of Otago) Research Interests: Medication adherence impact on outcomes, population pharmacokinetic modeling, model-informed dosing, therapeutic drug monitoring, and renal drug dosing. His work emphasizes translating pharmacometric insights into clinical practice to improve patient outcomes in chronic conditions like gout. Articles Trends: Recent publications highlight advancements in allopurinol dosing algorithms for gout, adherence measurement tools, and pharmacogenomic factors influencing drug response. His work often bridges clinical research with practical guidelines for optimizing medication therapy. Awards: Repeated School of Pharmacy Best Lecturer Award (2019–2023) Emerging Researcher Award (2018) Top Editor Prize (BJCP, 2018–2019) Advising/Grants: Lead the FMH Start-up Scheme grant (2024) for clinical pharmacology projects. Active in mentoring editorial boards (e.g., British Journal of Clinical Pharmacology) and professional societies like ASCEPT. Labs/Teams: Leads the Easy-Allo Study team for gout dosing innovation and chairs ASCEPT's environmental sustainability portfolio. Collaborates internationally on pharmacometric and adherence research initiatives.
Prof. Gunnar Rätsch is a Full Professor in the Department of Computer Science at ETH Zürich and Deputy Head of the Institute for Machine Learning. His research focuses on developing machine learning methods for biomedical applications, including genomics, medical imaging, and clinical decision support systems. He specializes in integrating multi-omics data, spatial transcriptomics, and time-series analysis to address challenges in precision medicine and critical care. His work emphasizes ethical AI frameworks, algorithmic fairness, and robust clinical prediction models. Key research areas include: Deep learning for medical imaging and histopathology Single-cell analysis and tumor profiling Reinforcement learning for treatment optimization in ICUs Multimodal data integration for clinical applications Recent work highlights advancements in: Standardizing single-cell cytometry readouts for clinical use Developing foundation models for critical care time-series analysis Creating interpretable survival models for ICU patients His contributions span foundational machine learning theory and applied healthcare technologies, with a focus on translational research to improve clinical outcomes. Current projects include the Tumor Profiler Study for multi-omic tumor analysis and ethical frameworks for clinical AI systems.
Nelianne Verkaik is a researcher at Erasmus MC in the Department of Medical Microbiology & Infectious Diseases. Her work focuses on antimicrobial resistance, infection control, and the management of device-related infections, particularly in critical care settings. She is actively involved in major research collaborations such as the DOLPHIN investigators and the SWAB Working Group Surveillance of Antimicrobial Resistance. Her research interests lie at the intersection of clinical microbiology and public health, with a strong emphasis on antibiotic sensitivity, carbapenemase-producing organisms, and the epidemiology of multidrug-resistant pathogens. A significant portion of her recent work investigates the spread of NDM-producing bacteria from Ukraine into Europe, highlighting the role of patient transfers in cross-border dissemination of resistant strains. The most recent articles reflect a consistent focus on optimizing antimicrobial therapy, assessing resistance patterns, and improving outcomes in critically ill patients. Her studies frequently employ retrospective analyses, genomic sequencing, and large-scale surveillance data to inform infection prevention strategies and antimicrobial stewardship programs. Scientific Awards: No scientific awards mentioned in the provided text. Advising and Grants: There is no explicit mention of student advising or grant funding in the provided information. However, her participation in multi-center studies such as the DOLPHIN trial suggests involvement in significant collaborative research projects, likely supported by external funding. She contributes as a key researcher in national and international efforts to monitor and combat antimicrobial resistance. Labs, Teams, and Networks: Dr. Verkaik collaborates extensively within the SWAB Working Group Surveillance of Antimicrobial Resistance and the DOLPHIN investigators. These networks involve multiple institutions across Europe and focus on antimicrobial resistance surveillance, precision dosing trials, and outbreak investigations. Her research leverages data from electronic health records, laboratory networks, and genomic surveillance systems.
Saskia de Wildt is a researcher at Erasmus MC in the Department of Neonatal and Pediatric Intensive Care. She is actively contributing to clinical pharmacology and pediatric medicine, with a strong focus on pharmacokinetics and individualized drug therapy in children and neonates. Her research interests span pharmacokinetics , physiologically based pharmacokinetic modeling , pharmacotherapy in pediatrics , off-label drug use , and model-informed precision dosing . Her work aims to improve drug safety and efficacy in vulnerable pediatric populations, particularly in intensive care settings. The recent publications highlight a strong trend in optimizing drug dosing during pregnancy and in critically ill children, leveraging computational modeling and systematic evidence synthesis. Her work bridges pharmacology, neonatology, and clinical implementation science. She has contributed to influential publications such as The Lancet Child & Adolescent Health and Clinical Pharmacology & Therapeutics , indicating recognition in high-impact journals. Her research has been cited in Scopus and picked up by news outlets and academic platforms like Mendeley and X. Saskia de Wildt has supervised 10 research projects, reflecting her role in mentoring the next generation of researchers in pediatric pharmacology. Although no specific grants are mentioned, her extensive output suggests active grant funding and collaborative research. She is affiliated with a leading research network in pediatric and neonatal intensive care at Erasmus MC, working in a multidisciplinary environment focused on advancing neonatal pharmacotherapy and critical care practices.
Inger-Karine Kolkman-Deurloo is a researcher at Erasmus MC, Department of Radiotherapy, Faculty of Medicine. Her work is centered on clinical and technical advancements in brachytherapy, particularly high-dose-rate (HDR) applications for prostate and cervical cancers. Research Interests: Her research spans brachytherapy treatment planning, electromagnetic tracking (EMT) for implant reconstruction, quality assurance, and patient-specific applicator development. Key areas include real-time in vivo monitoring, error detection in intraoperative settings, and improving accuracy in gynecological and prostate brachytherapy. She leverages advanced imaging and tracking technologies to enhance treatment precision. The recent publications (2024–2025) reflect a strong trend toward integrating EMT with afterloaders for automated applicator reconstruction, error detection in ultrasound-guided procedures, and developing tailored solutions for cervical cancer brachytherapy. These works emphasize clinical translation, reproducibility, and technological innovation in radiation oncology. Scientific Contributions: Active contributor to 54 research outputs including articles, abstracts, and a doctoral thesis. Focus on improving safety and accuracy in brachytherapy through engineering and medical physics solutions. Advising and Grants: No formal students or grant information is available in the provided text. However, her collaborative work suggests involvement in multidisciplinary research teams involving physicists, oncologists, and engineers. Labs and Teams: She collaborates within a clinical research environment at Erasmus MC, likely part of a radiotherapy physics or brachytherapy innovation team, working closely with experts in oncology, medical technology, and surgical engineering.
Chris Wiggins is an Associate Professor of Applied Mathematics and Systems Biology at Columbia University, with affiliations in the Department of Statistics. He is based in the School of Engineering and Applied Science and conducts interdisciplinary research at the intersection of data science, machine learning, and biological systems. His work bridges computational modeling with applications in genomics, single-molecule biophysics, digital health, and disinformation studies. His research interests include: Data Science and its societal implications Machine learning for biological networks and gene regulation Bayesian and statistical inference in single-molecule experiments Privacy-aware data analysis and algorithmic ethics Modeling in digital health, including menstrual cycle prediction and cancer drug screening Information-theoretic approaches to network structure and dynamics The trends in his recent publications reveal a growing focus on the ethical and societal dimensions of data science, as seen in works like How Data Happened and An Agenda for Disinformation Research , while maintaining strong technical contributions in biomedical modeling, particularly in cancer and women’s health. His work combines rigorous statistical methods with real-world data challenges. Notable scientific contributions include foundational work on ARACNE for gene regulatory network inference, Bayesian modeling of single-molecule dynamics, and methodological advances in dose-response modeling. His publications span top journals in bioinformatics, computational biology, and data science. He has advised doctoral students in applied mathematics and computational biology, though specific names are not listed in the provided text. His research has been supported by interdisciplinary grants, particularly in systems biology and data science initiatives. He is actively involved in shaping the philosophy and pedagogy of data science as a field. Chris Wiggins is associated with research centers at Columbia that focus on applied statistics, probability, and data science. He contributes to seminars and educational programs that promote quantitative reasoning across disciplines, particularly in the context of modern data-driven challenges.
Claudia Langebrake serves as a Privatdozent (equivalent to Professor) at the University Medical Center Hamburg-Eppendorf (UKE), which is affiliated with the University of Hamburg. She maintains dual appointments in the Department of Pharmacy and the Interdisciplinary Clinic and Polyclinic for Stem Cell Transplantation, reflecting her expertise at the intersection of clinical pharmacy and specialized medical care. With an active research profile documented by 81 publications, Dr. Langebrake has established herself as a leading authority in medication safety, therapeutic drug monitoring, and specialized pharmacotherapy. Dr. Langebrake's research spans several critical domains of modern pharmacy practice. Her work in stem cell transplantation pharmacology has produced influential guidelines for therapeutic drug monitoring of busulfan and other critical medications, with significant contributions to the European Society for Blood and Marrow Transplantation's Pharmacist Committee. In geriatric pharmacotherapy, she has conducted important longitudinal studies on anticholinergic drug burden in older adults and developed interventions for safe medication management in elderly populations. Her research on CAR-T cell therapy management addresses emerging challenges in novel immunotherapies, where she has co-authored practical implementation guidelines for pharmacists. Analysis of Dr. Langebrake's publication trends reveals a consistent focus on translating pharmaceutical science into practical clinical applications. Her work on medication safety in oncology settings has led to improved protocols for handling hazardous drugs, while her research on quality assessment frameworks for hospital pharmacy services has informed national standards in Germany. The evolution of her research from foundational medication safety studies to cutting-edge work on novel immunotherapies demonstrates her ability to address emerging challenges in pharmaceutical care. Dr. Langebrake has been instrumental in developing the DokuPIK 2.0 database for documenting pharmaceutical interventions and has contributed extensively to national quality assessment initiatives through the ADKA (Arzneimittelkommission der deutschen Ärzteschaft). Her collaborative work spans multiple institutions in Germany and internationally, reflecting her standing as a thought leader in clinical pharmacy who bridges pharmaceutical science with direct patient care applications.
James P. Allison is Regental Professor and Chair of the Department of Immunology at The University of Texas MD Anderson Cancer Center, where he also holds the Olga Keith Wiess Distinguished University Chair for Cancer Research. He serves as Director of the James P. Allison Institute, Executive Director of the Immunotherapy Platform, and Director of the Parker Institute for Cancer Immunotherapy. His pioneering work in T cell biology and immune checkpoint blockade has revolutionized cancer treatment. Research Interests: Dr. Allison’s research centers on the regulation of T cell responses and the development of cancer immunotherapies. He is best known for discovering that blocking the CTLA-4 protein enhances T cell activation and enables tumor rejection. His work laid the foundation for immune checkpoint inhibitors, a transformative class of cancer drugs. Current research focuses on improving existing therapies, identifying new immune targets, and understanding mechanisms of response and resistance across cancers. His lab integrates basic immunology with translational and clinical research to accelerate therapeutic breakthroughs. Scientific Trends in Publications: His recent publications reflect a sustained focus on immune checkpoint biology, mechanisms of resistance, co-stimulatory pathways, and next-generation immunotherapies. The work spans from fundamental T cell signaling to clinical translation, emphasizing biomarker discovery, combination strategies, and personalized treatment approaches. There is a clear trend toward interdisciplinary collaboration, reverse translational research, and leveraging data science to inform laboratory studies. Scientific Awards and Honors: Nobel Prize in Physiology or Medicine (2018) Lasker-DeBakey Clinical Medical Research Award (2015) Member, National Academy of Sciences Member, National Academy of Medicine Kovalenko Medal, National Academy of Sciences TIME 100 Most Influential People William B. Coley Award Szent-Györgyi Prize for Progress in Cancer Research Crafoord Prize in Polyarthritis American Association of Immunologists Lifetime Achievement Award Advising, Grants, and Leadership: Dr. Allison has mentored numerous graduate students, postdoctoral fellows, and early-career scientists across institutions including MD Anderson, UC Berkeley, and Memorial Sloan Kettering. He leads large collaborative initiatives such as the Stand Up To Cancer-Cancer Research Institute Cancer Immunology Dream Team and the Parker Institute for Cancer Immunotherapy. His research has been supported by major grants from the National Institutes of Health (NIH), National Cancer Institute (NCI), Cancer Prevention & Research Institute of Texas (CPRIT), Howard Hughes Medical Institute (HHMI), Cancer Research Institute, Prostate Cancer Foundation, and Stand Up to Cancer. Labs and Research Teams: Dr. Allison leads the Allison Lab at MD Anderson and co-leads the Immunotherapy Platform with Dr. Padmanee Sharma. The James P. Allison Institute, launched in 2022, serves as a multidisciplinary hub for immunobiology research, integrating discovery, translational, and clinical science. The institute fosters dynamic, project-focused teams across disciplines and collaborates with pharmaceutical partners to accelerate drug development. It is supported by MD Anderson’s Therapeutics Discovery division, core research platforms, and data science infrastructure.
Björn Morén is an Assistant Professor in the Department of Mathematics at Linköping University, Sweden. He is affiliated with the Division of Applied Mathematics (TIMA), where his research focuses on mathematical optimization applied to brachytherapy treatment planning in radiation oncology. His work aims to improve cancer treatment outcomes through advanced computational models that enhance precision and robustness in radiotherapy. Research Interests: His primary research lies at the intersection of applied mathematics and medical physics. He specializes in developing and analyzing mathematical optimization models for high-dose-rate (HDR) brachytherapy, particularly for prostate and cervical cancers. His work addresses critical challenges such as rotational and positional uncertainties, dwell time optimization, and automated plan validation. He seeks to bridge the gap between manual clinical planning and algorithm-driven optimization to improve dosimetric outcomes and reduce complications. Publication Trends: His recent publications (2021–2025) demonstrate a consistent focus on robust optimization techniques in brachytherapy. Themes include uncertainty mitigation, dosimetric evaluation, inverse planning, and automation in treatment workflows. His interdisciplinary work combines operations research, medical imaging, and clinical oncology, reflecting strong collaboration across physics and medicine. Scientific Awards: No awards or honors are mentioned in the provided text. Advising and Grants: There is no information available about students advised or research grants received. However, his active publication record suggests ongoing funded research and potential mentorship roles within his research group. Labs and Teams: Björn Morén is part of a multidisciplinary research group at Linköping University focused on brachytherapy treatment planning. This group collaborates on developing optimization models for clinical use, working closely with medical physicists and oncologists to translate mathematical innovations into practical healthcare solutions.
Prof. Dr. Annette Kopp-Schneider is Head of Department at the German Cancer Research Center (DKFZ) and affiliated with the Faculty of Medicine at the University of Heidelberg. She holds a professorial rank and leads research in medical biometry with a focus on clinical trial methodology in precision oncology. Diploma in Mathematics, RWTH Aachen, 1984 Dr. rer. nat. in Mathematics, RWTH Aachen, 1987 Habilitation in Medical Biometry, University of Heidelberg, 1997 Her research interests include clinical trials for precision oncology , dose-response modeling , and biologically based mechanistic modeling of cell systems . She develops advanced statistical methods for trial design, particularly in pediatric oncology and settings with small sample sizes. Her work emphasizes rigorous control of type I error when borrowing historical data and optimal experimental designs for drug combinations. The recent publications reflect a strong trend in methodological biostatistics , particularly in Bayesian and frequentist approaches to clinical trial design , external data incorporation , and transparent evaluation in biomedical image analysis . Her contributions span oncology, toxicology, and translational medicine, with a consistent focus on statistical rigor and reproducibility. She has contributed to major initiatives such as the Pediatric Precision Oncology INFORM Registry, advancing personalized treatment for children with cancer. Her methodological work supports fair comparisons in hybrid and single-arm trials and improves the reliability of challenge-based research in medical imaging. Prof. Kopp-Schneider is actively engaged in grant-funded research and mentoring within her department. She leads a team focused on biostatistical innovation in clinical research, particularly in oncology settings where data are sparse and traditional designs face limitations. She is involved in collaborative teams working on biomedical image analysis challenges and pediatric cancer registries. Her lab contributes to open science through toolkits for challenge analysis and transparent reporting guidelines like BIAS (Transparent Reporting of Biomedical Image Analysis Challenges).
Kim Brøsen is Professor of Clinical Pharmacology in the Department of Health Services Research at the University of Southern Denmark. Since 1995 he has led research into pharmacokinetics and pharmacogenetics, focusing on genetic determinants of drug metabolism and transport. Education: 1988 – Dr.med. in Clinical Pharmacology, Faculty of Health Sciences, Odense University 1981 – Cand.med., University of Copenhagen Research Interests: Professor Brøsen’s core research area is pharmacokinetics , with particular emphasis on genetic polymorphisms affecting hepatic drug metabolism (e.g., CYP2D6 and CYP2C19) and, more recently, on genetic control of drug transport across cellular membranes . These investigations bridge basic pharmacology and clinical applications, underpinning personalized medicine strategies. Across more than 380 peer-reviewed publications, his recent work has concentrated on population pharmacokinetic modelling of tacrolimus in kidney transplant patients, the influence of antibiotics on P-glycoprotein-mediated drug transport, and metformin pharmacogenomics. These studies collectively advance understanding of variability in drug response and inform evidence-based dosing algorithms. Scientific Awards: BCPT Nordic Prize in Pharmacology and Toxicology (2022) EACPT Lifetime Achievement Award (2022) PhD Supervision & Mentoring: Professor Brøsen has formally supervised at least four PhD students to completion and continues to mentor junior researchers within his department’s clinical pharmacology group. Collaborative Networks & Labs: His research is embedded in an extensive international collaboration network spanning Europe and North America, reflected in multi-centre pharmacokinetic and pharmacogenetic trials. The department hosts state-of-the-art analytical and modelling facilities supporting translational pharmacology research.
Erwin Dreesen is a tenure-track Lecturer at KU Leuven's Faculty of Pharmaceutical Sciences, affiliated with the Department of Pharmaceutical and Pharmacological Sciences. He leads the Clinical Pharmacology and Pharmacotherapy unit and holds memberships in KU Leuven's iSi Health Institute (physics-based modeling) and Leuven One Health Institute. His committee roles include the Research Ethics Committee UZ/KU Leuven and Faculty Councils. His research specializes in pharmacometrics , therapeutic drug monitoring , and precision dosing , with projects spanning: Model-informed dosing of immunosuppressants in transplant patients Antimicrobial optimization in critical care Geriatric pharmacokinetics Biologics for inflammatory diseases He coordinates 10+ active grants (2021-2029) as promoter/co-promoter, including studies on tacrolimus dosing, crizanlizumab for sickle cell disease, and antimicrobial strategies. Recent publications (2022-2025) demonstrate: Advanced pharmacometric modeling techniques Focus on clinical applications in IBD, antifungal therapy, and geriatrics Emphasis on personalized dosing algorithms and therapeutic monitoring He teaches courses including Pharmacometrics, Drug Development, Thesis Supervision, and Research Methodology.
Edoardo G. Ostinelli, MD, DPhil, is Senior Researcher and Deputy Lead of the Oxford Precision Psychiatry Lab (OxPPL) within the Department of Psychiatry at the University of Oxford. He concurrently serves as CRF Senior Medic at the NIHR Oxford Cognitive Health Clinical Research Facility and as Honorary Consultant Psychiatrist for Oxford Health NHS Foundation Trust. Education & Qualifications: Doctor of Philosophy (DPhil), University of Oxford Doctor of Medicine (MD), qualified Psychiatrist Research Focus: Dr Ostinelli’s programme centres on translating evidence-based medicine into real-world psychiatric practice. He designs and evaluates precision-medicine tools that integrate individual patient preferences with large-scale trial and observational data, exemplified by the PETRUSHKA web-based clinical decision-support system for antidepressant selection in depression. Additional work spans network meta-analyses of psychological and pharmacological interventions across depression, insomnia, ADHD, PTSD, and schizophrenia, as well as living systematic reviews that incorporate AI-assisted screening techniques. Collaborations & Impact: His studies routinely involve international consortia with academic centres in Bern, Kyoto, London, Munich, Ottawa, Tokyo and Toronto. Outputs have informed WHO and NICE guidance and have been widely cited in both scientific and lay media. Teaching & Capacity Building: Lecturer, MSc Clinical & Therapeutic Neuroscience, University of Oxford Lecturer, Master in Evidence-Based Therapeutic Approaches, University of Verona Instructor, Oxford Courses on Systematic Review & Meta-Analysis and Network Meta-Analysis Selected Recent Trends in Publications: Across 2024-2025 Dr Ostinelli has led or co-authored high-impact syntheses on personalised antidepressant treatment, comparative safety of ADHD medications, digital sleep phenotyping in psychosis, and methodological advances in living systematic reviews using large-language models. This portfolio reflects an expanding emphasis on digital health technologies, precision therapeutics, and rigorous comparative-effectiveness methodology.
